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Background: Increased cardiac lipid content has been associated with diabetic cardiomyopathy. We recently
showed that cardiac lipid content is reduced after 12 weeks of physical activity training in healthy overweight
subjects. The beneficial effect of exercise training on cardiovascular risk is well established and the decrease in
cardiac lipid content with exercise training in healthy overweight subjects was accompanied by improved ejection
fraction. It is yet unclear whether diabetic patients respond similarly to physical activity training and whether a
lowered lipid content in the heart is necessary for improvements in cardiac function. Here, we investigated
whether exercise training is able to lower cardiac lipid content and improve cardiac function in type 2 diabetic
patients.
Methods: Eleven overweight-to-obese male patients with type 2 diabetes mellitus (age: 58.4 ± 0.9 years, BMI: 29.9
± 0.01 kg/m
2) followed a 12-week training program (combination endurance/strength training, three sessions/
week). Before and after training, maximal whole body oxygen uptake (VO2max) and insulin sensitivity (by
hyperinsulinemic, euglycemic clamp) was determined. Systolic function was determined under resting conditions
by CINE-MRI and cardiac lipid content in the septum of the heart by Proton Magnetic Resonance Spectroscopy.
Results: VO2max increased (from 27.1 ± 1.5 to 30.1 ± 1.6 ml/min/kg, p = 0.001) and insulin sensitivity improved
upon training (insulin stimulated glucose disposal (delta Rd of glucose) improved from 5.8 ± 1.9 to 10.3 ± 2.0
μmol/kg/min, p = 0.02. Left-ventricular ejection fraction improved after training (from 50.5 ± 2.0 to 55.6 ± 1.5%, p
= 0.01) as well as cardiac index and cardiac output. Unexpectedly, cardiac lipid content in the septum remained
unchanged (from 0.80 ± 0.22% to 0.95 ± 0.21%, p = 0.15).
Conclusions: Twelve weeks of progressive endurance/strength training was effective in improving VO2max, insulin
sensitivity and cardiac function in patients with type 2 diabetes mellitus. However, cardiac lipid content remained
unchanged. These data suggest that a decrease in cardiac lipid content in type 2 diabetic patients is not a
prerequisite for improvements in cardiac function.
Trial registration: ISRCTN: ISRCTN43780395
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The prevalence of heart failure continues to increase.
The life time risk to develop heart failure is presently
20% [1] and type 2 diabetes mellitus independently
increases the risk for developing heart failure [2]. In
addition to the well-known diabetes-associated risk of
coronary atherosclerosis, also metabolic changes and
increased triglyceride deposition in the diabetic myocar-
d i u ma r el i k e l yt oc o n t r i b u t et ot h ed e v e l o p m e n to f
compromised cardiac function in patients with type 2
diabetes.
While most fatty acids (FA) in the body are stored in
adipose tissue, small but physiologically relevant amounts
are stored in non-adipose tissues such as skeletal muscle,
liver, pancreas and the heart. In the heart, this (ectopic)
fat storage has been suggested to interfere with insulin
signaling and to induce apoptosis, which may contribute
to impaired cardiac function, a process coined cardiac
“lipotoxicity”. Thus, lean rodent models with targeted
overexpression of genes involved in lipid delivery and
synthesis in the myocardium show lipid accumulation-
induced dilated cardiomyopathy and heart failure in the
absence of obesity-related cardiovascular risk factors
(such as hypertension or dyslipidemia) [3-5], indicating
that lipid accumulation in the myocardium can cause
cardiomyopathy directly. Moreover, treatments amelior-
ating cardiac lipid accumulation rescued the heart from
dilated cardiomyopathy in rodents [6,7].
In humans, cardiac lipid accretion has been reported in
obesity and even more so in type 2 diabetes [8-10]
although human data is still limited due to the fact that
cardiac tissue samples are not readily available. Only
recently, non-invasive lipid quantification in the septum of
the heart using magnetic resonance spectroscopy has been
established [11,12]. With this methodology, several studies
showed inverse relations between cardiac lipid content
and systolic and diastolic function [9-11], suggesting that
excessive lipid accumulation in the heart may indeed
impair normal cardiac function and result in cardiomyopa-
thy and contribute to the increased risk of heart failure in
type 2 diabetic patients [13]. However, whether a decrease
in cardiac lipid content is necessary for improvement of
cardiac function is presently unknown.
In that respect, we recently showed that endurance
training reduced cardiac lipid content in parallel with an
improvement in left ventricular ejection fraction in
healthy, obese subjects [14]. It is well known that physical
exercise training improves insulin sensitivity and reduces
cardiac risk factors also in diabetic subjects. Hence, both
the American Diabetes Association and American Heart
Association promote regular physical exercise to reduce
morbidity in type 2 diabetic patients [15]. Whether exer-
cise training is also able to reduce cardiac lipid content in
type 2 diabetic patients is presently unknown, and is the
aim of the present study.
Methods
Subjects
Eleven male type 2 diabetic patients were included in this
study. Diabetes had to be diagnosed for at least one year
before the start of the study (on average: 3.5 ± 1.1 years)
and was confirmed during screening (based on fasting
plasma glucose concentrations of 7.0 mmol/l or higher, in
accordance with the definition of the American Diabetes
Association, ADA); diabetes was well-controlled in all sub-
jects (HbA1c = 7.1 ± 0.2%). Exclusion criteria were: systo-
lic blood pressure > 160 mm Hg or diastolic blood
pressure > 100 mm Hg and known cardiac disease. Sub-
jects’ characteristics are listed in table 1. None of the
patients was using insulin therapy; only oral anti-diabetic
agents were used (metformin only (n = 6), metformin in
combination with SU derivatives (n = 2) or SU derivatives
only (n = 2)). Lipid-lowering medication was used by
seven patients (six patients used statins, one patient used
fibrates), some patients used blood pressure lowering med-
ication (n = 5, of which 2 beta blokkers) or blood diluents
(n = 4). Patients continued their normal medication
throughout the study, except for antidiabetic medication
which was stopped one week before the determination of
insulin sensitivity. The study was approved by the institu-
tional medical ethical committee and written informed
consent was obtained from all participants.
Study protocol
Body composition, maximal oxygen uptake, insulin sen-
sitivity, cardiac function and fat content, and fasting
plasma concentration of fatty acids (FA), triacylglycerols,
Table 1 Subjects’ characteristics before and after the
training intervention period of 12 weeks
before training after training p-value
age (y) 59.5 ± 0.9 - -
BMI (kg/m
2) 30.5 ± 1.4 30.4 ± 1.4 0.8
Fat percentage (%) 30.3 ± 2.1 29.1 ± 2.1 0.11
VO2max (ml/kg/min) 27.1 ± 1.5 30.1 ± 1.6 0.001*
delta Rd (μmol/kg/min) 5.8 ± 1.9 10.3 ± 2.0 0.02 *
glucose (mMol) 9.1 ± 0.6 9.3 ± 0.6 0.6
HbA1c (%) 7.1 ± 0.2 7.2 ± 0.3 0.5
FA (μmol/l) 478.4 ± 54.2 526.3 ± 71.3 0.2
Total cholesterol (mmol/l) 4.9 ± 0.2 4.6 ± 0.3 0.3
HDL cholesterol (mmol/l) 1.2 ± 0.1 1.2 ± 0.1 0.6
LDL cholesterol (mmol/l) 2.7 ± 0.2 2.6 ± 0.2 0.4
Triacylglycerols (mmol/l) 2.1 ± 0.2 1.9 ± 0.2 0.4
Stars indicate statistically significant changes.
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and after a 12-week well-controlled exercise program,
consisting of a combination of aerobic and resistance
exercise with three training sessions per week, carried
out in small groups of 4 subjects, supervised by a coach,
see [14].
Maximal oxygen uptake (whole body oxidative capacity)
A routine incremental cycling test was used to deter-
mine the maximal aerobic capacity as described earlier
(Oxycon Beta, Mijnhardt, The Netherlands) [14].
Insulin sensitivity
Insulin sensitivity was measured with a hyperinsulinemic
(40 mU/m
2/min) euglycemic clamp, see [14]. Patients
were asked to keep a constant eating pattern and to
refrain from intense physical exercise during the last
three days before the clamp.
Hydrostatic weighing
Hydrostatic weighing with simultaneous measurement of
lung volume was used to determine whole body fat per-
centage in the morning in the fasted state. The equation
of Siri [16] was used to calculate fat percentage, fat
mass and fat-free mass.
Blood sample analysis
Blood samples were collected in EDTA-containing
tubes and immediately centrifuged at high speed.
Plasma FA, glucose and glycosylated haemoglobin were
measured as described previously [14]. Total choles-
terol, HDL-cholesterol and triacylglycerol were ana-
lyzed in serum enzymatically as described previously
[14].
MRI
An electrocardiographically triggered balanced steady state
free precession (bSSFP) cine sequence was used to acquire
images in two- and four chamber views and to image the
whole heart in the short-axis orientation during breath
holds (Intera, 1.5T, Philips Healthcare, Best, The Nether-
lands). Slice thickness was 6 mm with a 4 mm gap (flip
angle = 50°; shortest possible TR (3.3 ms) and TE (1.67
ms); field of view = 350 × 350 mm, reconstructed matrix =
256 × 256, number of heart phases = 24). Cine images
were analyzed using dedicated software (CAAS, Pie Medi-
cal Imaging, Maastricht, The Netherlands) to determine
left ventricular end-systolic and end-diastolic volume.
From this, parameters of systolic function were calculated
(ejection volume, cardiac output, cardiac index). For one
patient, the MRI procedure had to be accelerated due to
anxiety and another patient had problems holding his
breath. From these two subjects, it was impossible to
acquire enough slices to cover the whole left ventricle and
systolic function could not be determined and is therefore
reported for nine subjects.
MRS
Cardiac lipid content was determined in vivo by Magnetic
Resonance Spectroscopy (MRS) as described previously
[14]. Signal acquisition was restricted to a volume of inter-
est of 6 cm
3 (10 mm × 20 mm × 30 mm) in the septum of
the heart (PRESS sequence; spectral bandwidth = 1000
Hz; points acquired = 512; TE = 26 ms; TR = 4 s; n = 128
for lipid spectrum, n = 16 for reference water spectrum),
signal acquisition was ECG-triggered to end-systole.
Respiratory gating and tracking was performed with a pen-
cil beam navigator placed on the diaphragm. A spectrum
of the lipid metabolites was acquired with water suppres-
sion (CHESS). As internal reference, water signal intensity
was determined in a spectrum with the water suppression
pulses off-resonance. Overall acquisition time (imaging
and spectroscopy) was 90 minutes. The coefficient of var-
iation in repeated measurements was 11% on average. See
figure 1 for a typical spectrum.
Peaks were fitted with Gaussian curves, imposing rela-
tive ratios of the amplitudes and line widths, using the
AMARES algorithm [17] in jMRUI [18]. The results are
displayed as ratios of the amplitudes of the CH2 peak
relative to the water peak (uncorrected for T1 and T2
relaxation).
Statistics
All data are presented as mean ± SEM. Statistical ana-
lyses were performed using SPSS 16.0 for Mac (SPSS
Inc., Chicago, IL). The effect of the intervention was
determined by a two-sided, paired student t-test (con-
sidered significant if p < 0.05). Sample size (n = 11) was
determined with b =0 . 8a n da = 0.05, assuming࿠ a࿠
similar࿠ effect size as we found earlier
Results
Maximal oxygen uptake
The training program resulted in an improved maximal
performance (from 200 ± 11 to 235 ± 13 Watt (p <
0.001). Accordingly, maximal whole body oxygen uptake
improved with training (from 27.1 ± 1.5 to 30.1 ± 1.6
ml/min/kg (p = 0.001)).
Body weight and whole body fat percentage
Body weight did not change with training (96.1 ± 4.0
a n d9 5 . 6±4 . 4k g ,p r e -a n dp o s t training, respectively,
p = 0.8). Similarly, fat percentage, total body fat and fat-
free mass remained unchanged (see table 1 for fat
percentage).
Plasma parameters
The training program did not affect fasting plasma glu-
cose, HbA1c, FA and triacylglycerol plasma concentration.
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terol concentrations were unchanged after training (see
table 1).
Insulin sensitivity
Insulin sensitivity measured as insulin-stimulated glu-
cose disposal (delta Rd) during a hyperinsulinemic,
euglycemic clamp improved significantly (from 5.8 ± 1.9
at baseline to 10.3 ± 2.0 mmol/kg/min after training,
p = 0.02).
Cardiac function and lipid content
Left ventricular end-diastolic volume was not affected by
training (180.3 ± 8.7 to 179.0 ± 6.5 ml, p = 0.8) while
end-systolic volume was reduced (from 89.6 ± 6.5 to
79.6 ± 4.5 ml, p = 0.004). The decreased end-systolic
volume after training translates into improvements of
similar magnitude (about 10%) of ejection fraction (from
50.5 ± 2.0 to 55.6 ± 1.5%, p = 0.01, see figure 2), cardiac
index (from 2.87 ± 1.61 to 3.14 ± 1.08 l*min
-1*m
-2,p=
0.026) and cardiac output (from 5.8 ± 0.3 to 6.4 ± 0.2
ml/min, p = 0.04) after the training intervention. Strik-
ingly, these adaptive changes occurred in the absence of
changes in cardiac lipid content (0.80 ± 0.22% to 0.95 ±
0.21%, p = 0.15, as shown in figure 3.
Ejection fraction, cardiac index and cardiac output did
not correlate with cardiac lipid content. Similarly,
changes in cardiac function were not related to changes
in cardiac lipid content.
Discussion
The most important finding of the present study is that in
this group of type 2 diabetic patients, a twelve-week train-
ing program, which increased aerobic capacity and insulin
sensitivity resulted in an improvement of systolic function,
Figure 2 Left ventricular ejection fraction improved with the
training intervention (p = 0.01).
Figure 1 A typical short axis view and a proton magnetic resonance spectrum, acquired from a volume of 10 × 20 × 30 mm
3
positioned in the septum of the heart. The peaks of the CH2 and CH3 groups of the fatty acids can be discriminated and the peaks of
Creatine (Cr) and trimethylammonium (TMA) are depicted in the figure.
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data suggest that a decrease in cardiac lipid content in
type 2 diabetic patients is not a prerequisite for improve-
ments in cardiac function. A limitation of the current
study is the relatively small number of patients included.
Exercise training is well established as a powerful tool
to reduce the risk for cardiovascular disease in type 2
diabetic patients [19-23]; however it is less clear whether
training can actually improve cardiac function in this
population. Data on the effect of training on systolic
function in type 2 diabetic subjects is limited, with only
one study reporting a positive effect [24] while others
do not [25,26]. In diabetic animal models, however, the
improvement in ejection fraction and fractional shorten-
ing with endurance training is well documented [27,28].
We previously reported improved ejection fraction in
obese but otherwise healthy human subjects in response
to exercise training [14]. Here, we show that a modest
but significant improvement in ejection fraction can also
occur in type 2 diabetic patients, in response to a rela-
tively short period of training.
Rodent studies strongly support the concept that
accumulation of triglycerides in cardiomyocytes causes
cardiac lipotoxicity, impairing cardiac function. In addi-
tion, several human studies report negative correlations
of triglyceride content with cardiac function as well
[9,11]. Some [29], but not all [30] human studies report
lowered cardiac lipid content upon thiazolidinediones.
Recently, we reported that in healthy overweight-to-
obese subjects, the training-induced improvement in
systolic function is accompanied by a decrease in cardiac
lipid, in line with the cardiac lipid hypothesis [14]. Intri-
guingly, though, exercise-induced improvement in car-
diac contractile function was not accompanied by a
decrease in lipid content in the patients with type 2 dia-
betes, rather cardiac lipid content tends to increase in
this population, although not significantly. Why type 2
diabetic patients are unresponsive towards training-
induced decrease in cardiac lipid content cannot be
deduced from the present study. It is important to note
that the cardiac lipid content in the present group of
diabetic subjects is similar as reported in healthy over-
weight subjects of similar age and BMI [14]. However,
when compared to healthy lean young men, cardiac
lipid content is clearly elevated by ~300% in the present
group of patients [31]. In other words, cardiac lipid con-
tent is elevated as expected based on BMI and age, how-
ever, it is not further elevated due to type 2 diabetes.
This may be due to the relatively healthy patients inves-
tigated in the current study. Although diabetic, patients
did not have any severe diabetes-related complications.
Additionally, plasma concentrations of FFA and TG
were also normal. However, although not elevated more
severely than expected based on BMI and age at base-
line, the cardiac lipid content was unresponsive to an
exercise intervention in the diabetic subjects and inter-
estingly, this differs from the response in healthy over-
weight subjects. It is yet unclear what is at the basis of
this differential response, but it is well known that car-
diac metabolism is altered in diabetes. For example, car-
diac insulin resistance, decreased metabolic flexibility,
mitochondrial dysfunction and excessive cardiac fat
uptake and oxidation all have been associated with the
diabetic state. Furthermore, a study in a diabetic animal
model demonstrated decreased responsiveness to beta
adrenergic stimulation in diabetic animals upon exercise
training while beta adrenergic stimulation increased in
control animals [32]. Future studies are needed to inves-
tigate whether these factors are contributing to the dif-
ferential response in diabetic patients to exercise
training resulting in the unchanged cardiac lipid
content.
Furthermore, the present findings demonstrate that
the training-induced improvement of systolic function
can occur independently of changes in cardiac lipid con-
tent. Generally, it is believed that the beneficial effect of
training on systolic- and diastolic function is based on
alterations of the Ca
2+ regulatory systems involved in
the excitation-contraction coupling and relaxation pro-
cesses [33]. According to the cardiac lipotoxicity theory,
there are potential mechanisms by which lipid accumu-
lation may interact directly with excitation-contraction
coupling. We here demonstrate that this is not pivotal:
the improved function with exercise training can occur
independently of changes in lipid content. Apparently,
the improvement of cardiac function does not necessa-
rily require decrease in cardiac lipids in type 2 diabetic
subjects. Similarly, it has been shown that pioglitazone
improves diastolic function in type 2 diabetic subjects
without changes in cardiac lipid content [30].
Figure 3 Cardiac lipid content. Cardiac lipid content before and
after the training intervention. Cardiac lipid content is expressed as
the relative intensity of the CH2 peak, compared to the
unsuppressed water resonance. Cardiac lipid content is unchanged
after the training intervention (p = 0.8).
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In conclusion, we report here that a twelve-week training
program, which increased maximal whole body oxygen
uptake and insulin sensitivity, resulted in an improve-
ment in ejection fraction, while cardiac lipid content was
unchanged. These results demonstrate that the training-
induced improvement in systolic function does not
necessarily require lowering of cardiac lipid availability.
More studies are needed to get insight in the clinical rele-
vance of cardiac lipid content and its relation with car-
diac metabolism and diabetic cardiomyopathy.
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